Skip to main content

Table 1 Overview of retrospective studies on the effects of antiplatelet medication in patients with traumatic brain injury

From: Clinical review: Traumatic brain injury in patients receiving antiplatelet medication

Study Inclusion criteria Antiplatelet therapy Number of subjects Mortality rate Major findings
Mina et al. 2002 [20] Posttraumatic ICH Aspirin 19 47% aspirin group; 8% control group Mortality significantly increased with aspirin therapy. No difference in mortality rates between aspirin and warfarin treated patients
Spektor et al. 2003 [23] Mild and moderate TBI, age >60 years Aspirin (100 mg/day) 110 NR Aspirin therapy had no effect on incidence of posttraumatic ICH after mild to moderate TBI
Ohm et al. 2005 [21] Posttraumatic ICH Aspirin, clopidogrel 90 23% antiplatelet group; 8% control group Mortality threefold increased with antiplatelet therapy. GCS <12 and age >76 years risk factors for death in patients on antiplatelet therapy
Jones et al. 2006 [24] All TBI, age >50 years Clopidogrel 43 7% clopidogrel group Clopidogrel-treated patients have higher rates of cranial surgery and episodes of rebleeds. More blood products were transfused in clopidogrel-treated patients
Wong et al. 2008 [25] All TBI Aspirin, clopidogrel 111 14% clopidogrel group; 3% aspirin group Clopidogrel-treated patients were more likely to be discharged to long-term inpatient facilities
Major et al. 2009 [22] All TBI Aspirin, clopidogrel 287 1.4% aspirin group Mortality rate 21% in patients on aspirin with posttraumatic ICH. Three of the four patients who died in the aspirin group deteriorated with a significant delay
Bonville et al. 2011 [26] All TBI Aspirin, clopidogrel 271 12.3% aspirin group; 9.3% clopidogrel group Use of antiplatelet agents did not affect mortality or length of hospital stay
  1. GCS, Glasgow Coma Scale; ICH, intracranial haemorrhage; TBI, traumatic brain injury.